Clinical Trial Update: Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa [Phase 2]

View source ↗

Summary

This Phase 2 trial in newborn infants in South Africa compares the TB vaccine candidate VPM1002 to BCG to evaluate safety and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• VPM1002 (recombinant Bacillus Calmette-Guérin vaccine (rBCG))

Snippet

Sponsor: Serum Life Science Europe GmbH | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED